Immunoadsorption in pemphigus

References

• Hertl M. Pemphigus. Autoimmune bullous skin disorders, M Hertl. Springer Science+Business Media, Cambridge, MA 2005; 45–70
   Google Scholar
• Schiltz JR, et al. Production of acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 1976; 67: 254–260
   PubMed Web of Science ®Google Scholar
• Farb RM, et al. Anti-epidermal-cell-surface pemphigus antibody detaches viable epidermal cells from culture plates by activation of proteinase. Proc Natl Acad Sci USA 1978; 75: 459–463
   PubMedGoogle Scholar
• Anhalt GJ, et al. lnduction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189–1196
   PubMed Web of Science ®Google Scholar
• Stanley JR. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 1993; 53: 291–325
   PubMed Web of Science ®Google Scholar
• Amagai M. Desmoglein as a target in autoimmunity and infection. J Am Acad Dermatol 2003; 48(2)244–252
   PubMedGoogle Scholar
• Grando SA. Cholinergic control of epidermal cohesion. Exp Dermatol 2006; 15: 265–282
   PubMed Web of Science ®Google Scholar
• Fiebiger E, et al. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998; 101(1)243–251
   PubMedGoogle Scholar
• Calkins CC, et al. Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J Biol Chem 2006; 281(11)7623–7634
   PubMed Web of Science ®Google Scholar
• Arredondo J, et al. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol 2005; 167(6)1531–1544
   PubMed Web of Science ®Google Scholar
• Grando SA. Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology 2000; 201: 290–295
   PubMed Web of Science ®Google Scholar
• Garrod DR, et al. Desmosomal cadherins. Curr Opin Cell Biol 2002; 14(5)537–545
   PubMed Web of Science ®Google Scholar
• Koch PJ, et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 1997; 137: 1091–1102
   PubMed Web of Science ®Google Scholar
• Amagai M, et al. Adsorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (desmoglein 3) produced by baculovirus. J Clin Invest 1994; 94: 59–67
   PubMed Web of Science ®Google Scholar
• Amagai M, et al. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 2000; 105: 625–631
   PubMed Web of Science ®Google Scholar
• Tsunoda K, et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 2003; 170(4)2170–2178
   PubMed Web of Science ®Google Scholar
• Cheng SW, et al. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147(2)261–265
   PubMed Web of Science ®Google Scholar
• Komai A, et al. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay. Br J Dermatol 2001; 144(6)1177–1182
   PubMedGoogle Scholar
• Sekiguchi M, et al. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol 2001; 167(9)5439–5448
   PubMedGoogle Scholar
• Anzai H, et al. Conformational epitope mapping of antibodies against desmoglein 3 in experimental murine pemphigus vulgaris. J Dermatol Sci 2004; 35(2)133–142
   PubMedGoogle Scholar
• Nguyen VT, et al. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000; 106(12)1467–1479
   PubMed Web of Science ®Google Scholar
• Nguyen VT, et al. The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol 1998; 134(8)971–980
   PubMedGoogle Scholar
• Nguyen VT, et al. Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. Am J Pathol 2000; 157(4)1377–1391
   PubMedGoogle Scholar
• Nguyen VT, et al. Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 2000; 275(38)29466–29476
   PubMedGoogle Scholar
• Braun N, Bosch T. Immunoadsorption, current status and future developments. Expert Opin Investig Drugs 2000; 9(9)2017–2038
   PubMed Web of Science ®Google Scholar
• Hershko AY, Naparstek Y. Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci 2005; 1051: 635–646
   PubMed Web of Science ®Google Scholar
• Nakaji S. Current topics on immunoadsorption therapy. Ther Apher 2001, 4: 301–305
   PubMedGoogle Scholar
• Asahi T, et al. Blood purification therapies using dextran sulfate cellulose columns liposorber and selesorb. Ther Apher Dial 2003; 7(1)73–77
   PubMedGoogle Scholar
• Ronspeck W, et al. Peptide based adsorbers for therapeutic immunoadsorption. Ther Apher Dial 2003; 7(1)91–97
   PubMed Web of Science ®Google Scholar
• Wallukat G, et al. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002; 347(22)1806
   PubMedGoogle Scholar
• Cotterill JA, et al. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1978; 98(2)243
   PubMedGoogle Scholar
• Lüftl M, et al. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149(3)598–605
   PubMedGoogle Scholar
• Schmidt E, et al. Protein A immunoadsorption: A novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148(6)1222–1229
   PubMedGoogle Scholar
• Shimanovich I, et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006, [Epub ahead of print]
   PubMedGoogle Scholar
• Eming R, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212(2)177–187
   PubMedGoogle Scholar
• Psaridi-Linardaki L, et al. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy. J Neuroimmunol 2005; 159(1,2)183–191
   PubMedGoogle Scholar
• Herrero-Gonzalez JE, et al. Immunoadsorption against two distinct epitopes on human type XVII collagen abolishes dermal-epidermal separation induced in vitro by autoantibodies from pemphigoid gestationis patients. Eur J Immunol 2006; 36(4)1039–1048
   PubMedGoogle Scholar
• Eming R, et al. Longterm efficacy of immunoadsorption, rituximab as a monotherapy or sequential therapy in recalcitrant pemphigus. (in preparation).
   Google Scholar
• Zillikens D, et al. Recommendations for use of immunopheresis in the treatment of autoimmune bullous diseases. (submitted).
   Google Scholar
• Schmaldienst S, et al. Intravenous immunoglobulin application following immunoadsorption: Benefit or risk in patients with autoimmune diseases?. Rheumatology (Oxford) 2001; 40(5)513–521
   PubMed Web of Science ®Google Scholar
• Pfütze M, et al. Introducing a novel autoimmune bullous skin disorder score (ABSIS) for pemphigus. Eur J Dermatol, (in revision)
   Google Scholar
• Schoen H, et al. Immunapheresis in paraneoplastic pemphigus. Arch Dermatol 1998; 134: 706–710
   PubMedGoogle Scholar
• Frost N, et al. Treatment of pemphigus vulgaris with protein A immunoadsorption. Case report of long-term history showing favourable outcome. Ann NY Acad Sci 2005; 1051: 591–596
   PubMedGoogle Scholar
• Herrero-González JE, et al. Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption. Clin Exp Dermatol 2005; 30: 519–522
   PubMed Web of Science ®Google Scholar
• Wöhrl S, et al. Pemphigoid gestationis: Treatment with immunoapheresis. J Dtsch Dermatol Ges 2003; 1: 126–130
   PubMedGoogle Scholar
• Niedermeier A, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 2006, (in revision)
   Google Scholar